Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma

By Vaishampayan Ulka   Heilbrun Lance   Shields Anthony   Lawhorn-Crews Jawana   Baranowski Karen   Smith Daryn   Flaherty Lawrence  

Investigational New Drugs, Vol. 25, Iss. 1, 2007-02 ,pp. : 69-75

Springer Publishing Company

Access to resources Recommend Favorite

Bevacizumab plus Interferon-α versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy: A Cost-Minimization Analysis

By Ravasio Roberto   Ortega Cinzia   Sabbatini Roberto   Porta Camillo  

Clinical Drug Investigation, Vol. 31, Iss. 7, 2011-07 ,pp. : 507-517

Adis International

Access to resources Recommend Favorite

A STAT3 polymorphism can be used to predict the response to interferon-α in patients with metastatic renal cell cancer

By  

Inpharma, Vol. 1, Iss. 1599, 2007-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Phase I trial of thalidomide and Interleukin-2 in patients with metastatic renal cell carcinoma

By Olencki Thomas   Malhi Sareena   Mekhail Tarek   Dreicer Robert   Elson Paul   Wood Laura   Bukowski Ronald  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 321-326

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of vinflunine in patients with metastatic renal cell carcinoma

By Goldstein D.   Ackland S.   Bell D.   Olver I.   Davis I.   Rosenthal M.   Toner G.   Pinel M.   Byrne M.  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 429-434

Springer Publishing Company

Access to resources Recommend Favorite